#RNA Sequencing #Lexogen #Ochre Bio

Lexogen and Ochre Bio: A Game Changer in Genomic Data

Lexogen, the prominent biotechnology firm based in Vienna, has reached a significant milestone in the world of RNA transcriptomics. Recently, the company announced the fruitful completion of a large-scale project that involved next-generation sequencing (NGS) of primary human hepatocytes, conducted in collaboration with Ochre Bio. With over 120,000 samples being processed, this project is poised to set new standards in the generation of functional genomics datasets that will enhance the development of RNA therapies for chronic liver diseases.

Project Insights

At the project's core, Lexogen's proprietary extraction-free, high-resolution gene expression profiling platform was employed to obtain comprehensive functional genomics data. This innovative approach showcases Lexogen’s advanced technologies and emphasizes their commitment to delivering high-quality results across various sample types, including challenging bio-banked FFPE samples and primary hepatocyte samples.

Ochre Bio, recognized for its work on RNA medicines, is dedicated to addressing under-treated chronic liver conditions. The collaboration not only integrates extensive datasets but also enables the development of causal pathway predictions essential for the identification of therapeutic targets. By harnessing its proprietary OBELiX software, Ochre Bio can interrogate gene biology in human cells, tissues, and whole livers. This AI-driven discovery engine accelerates the process of target prioritization in drug development.

Importance of High-Fidelity Data